Less Is More: Destiny Phase IIb Trial Population Reduced
Move Agreed With FDA Will Speed Up XF-73 Trial
Destiny’s Phase IIb clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections got a boost from trial protocol amendments agreed with the FDA.
You may also be interested in...
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.
T-knife, a developer of T-cell receptors intended for T-cell therapy in solid tumor cancers, says the series A gives its development program three years of financial runway.
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.